CSL Plasma, the plasma collection business of global biotherapeutics leader CSL Behring, has been recognized as a 2022 Business of the Year finalist by the South Florida Business Journal.
CSL Plasma was recognized in part for its growth, such as opening its 300th U.S. plasma donation center in Greenacres, Florida, and innovation, such as the advancement of new plasmapheresis device technology that will roll out to U.S. plasma centers.
2022 is the second year the company has been named one of top three finalists in its category, which included companies of the same size based on revenue. Criteria for the award are:
- Strong financials that demonstrate ability to be a success;
- Leadership team strength;
- Culture and innovation; and
- Foundation of charitable and community outreach.
Plasma donations are essential as human plasma is used to produce therapies that treat diseases such as primary immunodeficiencies, hereditary angioedema, inherited respiratory disease, hemophilia, and other bleeding and neurological disorders.
“Plasma donation is a people-centric business,” said CSL Plasma General Manager Michelle Meyer. “Our employees, donors and patients are a critical chain as CSL Plasma continues to collect life-saving plasma donations to help make life-saving medicines for patients around the world. Our employees in South Florida – and around the world – have stayed focused while demonstrating creativity, flexibility and resilience in continuing to do their jobs and doing them well.”
The 2022 Business of the Year celebration took place April 14 at Jungle Island in Miami. Learn more: 2022 Business of the Year winners and finalists in revenue categories
About CSL Plasma
CSL Plasma, operates one of the world’s largest and most sophisticated plasma collection networks, with more than 300 plasma collection centers in the U.S., Europe and China. Headquartered in Boca Raton, Florida, CSL Plasma is a subsidiary of CSL Behring, a global biotherapeutics company and a member of the CSL Group of companies. Plasma collected at CSL Plasma facilities is used by CSL Behring for the sole purpose of manufacturing lifesaving plasma-derived therapies for people in more than 100 countries. The parent company, CSL Limited (ASX:CSL; USOTC:CSLLY), headquartered in Melbourne, Australia, employs more than 25,000 people. For more information about CSL Plasma visit, www.cslplasma.com.